nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydralazine—RYR2—thyroid gland—thyroid cancer	0.0383	0.129	CbGeAlD
Hydralazine—AOC3—saliva-secreting gland—thyroid cancer	0.0378	0.127	CbGeAlD
Hydralazine—RYR2—head—thyroid cancer	0.034	0.114	CbGeAlD
Hydralazine—P4HA1—saliva-secreting gland—thyroid cancer	0.0302	0.102	CbGeAlD
Hydralazine—AOC3—trachea—thyroid cancer	0.0292	0.0982	CbGeAlD
Hydralazine—P4HA1—trachea—thyroid cancer	0.0233	0.0785	CbGeAlD
Hydralazine—AOC3—thyroid gland—thyroid cancer	0.0231	0.0777	CbGeAlD
Hydralazine—AOC3—head—thyroid cancer	0.0205	0.0689	CbGeAlD
Hydralazine—RYR2—Arrhythmogenic Right Ventricular Cardiomyopathy—TCF7L1—thyroid cancer	0.0186	0.163	CbGpPWpGaD
Hydralazine—P4HA1—thyroid gland—thyroid cancer	0.0185	0.0621	CbGeAlD
Hydralazine—Proteinuria—Vandetanib—thyroid cancer	0.0167	0.0284	CcSEcCtD
Hydralazine—Protein urine present—Vandetanib—thyroid cancer	0.0165	0.0281	CcSEcCtD
Hydralazine—RYR2—Arrhythmogenic Right Ventricular Cardiomyopathy—LAMA2—thyroid cancer	0.0165	0.144	CbGpPWpGaD
Hydralazine—P4HA1—head—thyroid cancer	0.0164	0.0551	CbGeAlD
Hydralazine—AOC3—lymph node—thyroid cancer	0.0143	0.0483	CbGeAlD
Hydralazine—RYR2—SIDS Susceptibility Pathways—RET—thyroid cancer	0.012	0.105	CbGpPWpGaD
Hydralazine—P4HA1—lymph node—thyroid cancer	0.0115	0.0386	CbGeAlD
Hydralazine—Proteinuria—Sorafenib—thyroid cancer	0.0113	0.0192	CcSEcCtD
Hydralazine—Polyneuropathy—Epirubicin—thyroid cancer	0.0113	0.0191	CcSEcCtD
Hydralazine—Protein urine present—Sorafenib—thyroid cancer	0.0111	0.0189	CcSEcCtD
Hydralazine—RYR2—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.0111	0.0973	CbGpPWpGaD
Hydralazine—Cardiac failure—Vandetanib—thyroid cancer	0.0109	0.0186	CcSEcCtD
Hydralazine—Polyneuropathy—Doxorubicin—thyroid cancer	0.0104	0.0177	CcSEcCtD
Hydralazine—Dysuria—Vandetanib—thyroid cancer	0.00863	0.0147	CcSEcCtD
Hydralazine—Neutropenia—Vandetanib—thyroid cancer	0.00863	0.0147	CcSEcCtD
Hydralazine—Weight decreased—Vandetanib—thyroid cancer	0.00835	0.0142	CcSEcCtD
Hydralazine—Hepatic function abnormal—Sorafenib—thyroid cancer	0.00824	0.014	CcSEcCtD
Hydralazine—Depression—Vandetanib—thyroid cancer	0.00821	0.0139	CcSEcCtD
Hydralazine—Conjunctivitis—Vandetanib—thyroid cancer	0.008	0.0136	CcSEcCtD
Hydralazine—Cardiac failure congestive—Sorafenib—thyroid cancer	0.00794	0.0135	CcSEcCtD
Hydralazine—Haematuria—Vandetanib—thyroid cancer	0.00785	0.0133	CcSEcCtD
Hydralazine—Renal failure acute—Sorafenib—thyroid cancer	0.0078	0.0133	CcSEcCtD
Hydralazine—RYR2—Calcium Regulation in the Cardiac Cell—PRKAR1A—thyroid cancer	0.00767	0.0671	CbGpPWpGaD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—PRKAR1A—thyroid cancer	0.00743	0.065	CbGpPWpGaD
Hydralazine—RYR2—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.00739	0.0646	CbGpPWpGaD
Hydralazine—Cardiac failure—Sorafenib—thyroid cancer	0.00738	0.0125	CcSEcCtD
Hydralazine—Lacrimation—Epirubicin—thyroid cancer	0.00624	0.0106	CcSEcCtD
Hydralazine—Muscle spasms—Vandetanib—thyroid cancer	0.00618	0.0105	CcSEcCtD
Hydralazine—Tremor—Vandetanib—thyroid cancer	0.00602	0.0102	CcSEcCtD
Hydralazine—RYR2—SIDS Susceptibility Pathways—SST—thyroid cancer	0.00584	0.0511	CbGpPWpGaD
Hydralazine—Neutropenia—Sorafenib—thyroid cancer	0.00582	0.00989	CcSEcCtD
Hydralazine—Lacrimation—Doxorubicin—thyroid cancer	0.00577	0.00981	CcSEcCtD
Hydralazine—RYR2—Myometrial Relaxation and Contraction Pathways—CALCA—thyroid cancer	0.00565	0.0494	CbGpPWpGaD
Hydralazine—Weight decreased—Sorafenib—thyroid cancer	0.00563	0.00957	CcSEcCtD
Hydralazine—Arthralgia—Vandetanib—thyroid cancer	0.00547	0.0093	CcSEcCtD
Hydralazine—Anxiety—Vandetanib—thyroid cancer	0.00546	0.00927	CcSEcCtD
Hydralazine—Neuropathy peripheral—Sorafenib—thyroid cancer	0.00544	0.00925	CcSEcCtD
Hydralazine—Jaundice—Sorafenib—thyroid cancer	0.00541	0.00919	CcSEcCtD
Hydralazine—Oedema—Vandetanib—thyroid cancer	0.00525	0.00892	CcSEcCtD
Hydralazine—Hepatomegaly—Epirubicin—thyroid cancer	0.00518	0.0088	CcSEcCtD
Hydralazine—Thrombocytopenia—Vandetanib—thyroid cancer	0.00514	0.00873	CcSEcCtD
Hydralazine—Neuritis—Epirubicin—thyroid cancer	0.00491	0.00835	CcSEcCtD
Hydralazine—Hepatomegaly—Doxorubicin—thyroid cancer	0.00479	0.00815	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00478	0.00812	CcSEcCtD
Hydralazine—Paraesthesia—Vandetanib—thyroid cancer	0.00471	0.00801	CcSEcCtD
Hydralazine—Dyspnoea—Vandetanib—thyroid cancer	0.00468	0.00795	CcSEcCtD
Hydralazine—Flushing—Sorafenib—thyroid cancer	0.00462	0.00786	CcSEcCtD
Hydralazine—Dyspepsia—Vandetanib—thyroid cancer	0.00462	0.00785	CcSEcCtD
Hydralazine—Decreased appetite—Vandetanib—thyroid cancer	0.00456	0.00775	CcSEcCtD
Hydralazine—Neuritis—Doxorubicin—thyroid cancer	0.00455	0.00772	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00453	0.0077	CcSEcCtD
Hydralazine—Constipation—Vandetanib—thyroid cancer	0.00449	0.00763	CcSEcCtD
Hydralazine—Blood disorder—Epirubicin—thyroid cancer	0.00439	0.00746	CcSEcCtD
Hydralazine—Muscle spasms—Sorafenib—thyroid cancer	0.00417	0.00709	CcSEcCtD
Hydralazine—Body temperature increased—Vandetanib—thyroid cancer	0.00415	0.00705	CcSEcCtD
Hydralazine—Blood disorder—Doxorubicin—thyroid cancer	0.00406	0.0069	CcSEcCtD
Hydralazine—Anaemia—Sorafenib—thyroid cancer	0.00401	0.00681	CcSEcCtD
Hydralazine—Lacrimation increased—Epirubicin—thyroid cancer	0.00398	0.00676	CcSEcCtD
Hydralazine—Leukopenia—Sorafenib—thyroid cancer	0.00388	0.0066	CcSEcCtD
Hydralazine—Pruritus—Vandetanib—thyroid cancer	0.00371	0.00631	CcSEcCtD
Hydralazine—Arthralgia—Sorafenib—thyroid cancer	0.00369	0.00628	CcSEcCtD
Hydralazine—Myalgia—Sorafenib—thyroid cancer	0.00369	0.00628	CcSEcCtD
Hydralazine—Lacrimation increased—Doxorubicin—thyroid cancer	0.00368	0.00626	CcSEcCtD
Hydralazine—Diarrhoea—Vandetanib—thyroid cancer	0.00359	0.0061	CcSEcCtD
Hydralazine—RYR2—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.00351	0.0307	CbGpPWpGaD
Hydralazine—Dizziness—Vandetanib—thyroid cancer	0.00347	0.0059	CcSEcCtD
Hydralazine—Thrombocytopenia—Sorafenib—thyroid cancer	0.00347	0.00589	CcSEcCtD
Hydralazine—Anorexia—Sorafenib—thyroid cancer	0.00337	0.00573	CcSEcCtD
Hydralazine—Vomiting—Vandetanib—thyroid cancer	0.00334	0.00567	CcSEcCtD
Hydralazine—Rash—Vandetanib—thyroid cancer	0.00331	0.00562	CcSEcCtD
Hydralazine—Dermatitis—Vandetanib—thyroid cancer	0.00331	0.00562	CcSEcCtD
Hydralazine—Headache—Vandetanib—thyroid cancer	0.00329	0.00559	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00323	0.00548	CcSEcCtD
Hydralazine—Dyspnoea—Sorafenib—thyroid cancer	0.00316	0.00536	CcSEcCtD
Hydralazine—Lymphadenopathy—Epirubicin—thyroid cancer	0.00312	0.0053	CcSEcCtD
Hydralazine—Nausea—Vandetanib—thyroid cancer	0.00312	0.0053	CcSEcCtD
Hydralazine—Dyspepsia—Sorafenib—thyroid cancer	0.00312	0.0053	CcSEcCtD
Hydralazine—Decreased appetite—Sorafenib—thyroid cancer	0.00308	0.00523	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00306	0.00519	CcSEcCtD
Hydralazine—Hepatic function abnormal—Epirubicin—thyroid cancer	0.00305	0.00518	CcSEcCtD
Hydralazine—Constipation—Sorafenib—thyroid cancer	0.00303	0.00514	CcSEcCtD
Hydralazine—Vascular purpura—Epirubicin—thyroid cancer	0.00298	0.00506	CcSEcCtD
Hydralazine—Cardiac failure congestive—Epirubicin—thyroid cancer	0.00294	0.00499	CcSEcCtD
Hydralazine—Lymphadenopathy—Doxorubicin—thyroid cancer	0.00289	0.00491	CcSEcCtD
Hydralazine—Renal failure acute—Epirubicin—thyroid cancer	0.00288	0.0049	CcSEcCtD
Hydralazine—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.00282	0.00479	CcSEcCtD
Hydralazine—Urticaria—Sorafenib—thyroid cancer	0.00281	0.00478	CcSEcCtD
Hydralazine—Body temperature increased—Sorafenib—thyroid cancer	0.0028	0.00476	CcSEcCtD
Hydralazine—Purpura—Epirubicin—thyroid cancer	0.00276	0.00469	CcSEcCtD
Hydralazine—Vascular purpura—Doxorubicin—thyroid cancer	0.00275	0.00468	CcSEcCtD
Hydralazine—Cardiac failure—Epirubicin—thyroid cancer	0.00273	0.00463	CcSEcCtD
Hydralazine—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.00272	0.00462	CcSEcCtD
Hydralazine—Renal failure acute—Doxorubicin—thyroid cancer	0.00267	0.00453	CcSEcCtD
Hydralazine—Hypersensitivity—Sorafenib—thyroid cancer	0.00261	0.00443	CcSEcCtD
Hydralazine—Purpura—Doxorubicin—thyroid cancer	0.00256	0.00434	CcSEcCtD
Hydralazine—RYR2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.00254	0.0222	CbGpPWpGaD
Hydralazine—RYR2—Transmembrane transport of small molecules—CP—thyroid cancer	0.00254	0.0222	CbGpPWpGaD
Hydralazine—Cardiac failure—Doxorubicin—thyroid cancer	0.00252	0.00429	CcSEcCtD
Hydralazine—Pruritus—Sorafenib—thyroid cancer	0.0025	0.00426	CcSEcCtD
Hydralazine—RYR2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.0025	0.0218	CbGpPWpGaD
Hydralazine—Diarrhoea—Sorafenib—thyroid cancer	0.00242	0.00412	CcSEcCtD
Hydralazine—Dizziness—Sorafenib—thyroid cancer	0.00234	0.00398	CcSEcCtD
Hydralazine—Eosinophilia—Epirubicin—thyroid cancer	0.00228	0.00387	CcSEcCtD
Hydralazine—Vomiting—Sorafenib—thyroid cancer	0.00225	0.00382	CcSEcCtD
Hydralazine—Angina pectoris—Epirubicin—thyroid cancer	0.00224	0.00381	CcSEcCtD
Hydralazine—Rash—Sorafenib—thyroid cancer	0.00223	0.00379	CcSEcCtD
Hydralazine—Dermatitis—Sorafenib—thyroid cancer	0.00223	0.00379	CcSEcCtD
Hydralazine—Headache—Sorafenib—thyroid cancer	0.00222	0.00377	CcSEcCtD
Hydralazine—Pancytopenia—Epirubicin—thyroid cancer	0.00219	0.00371	CcSEcCtD
Hydralazine—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.00217	0.019	CbGpPWpGaD
Hydralazine—Dysuria—Epirubicin—thyroid cancer	0.00215	0.00366	CcSEcCtD
Hydralazine—Neutropenia—Epirubicin—thyroid cancer	0.00215	0.00366	CcSEcCtD
Hydralazine—Eosinophilia—Doxorubicin—thyroid cancer	0.00211	0.00358	CcSEcCtD
Hydralazine—Nausea—Sorafenib—thyroid cancer	0.0021	0.00357	CcSEcCtD
Hydralazine—Weight decreased—Epirubicin—thyroid cancer	0.00208	0.00354	CcSEcCtD
Hydralazine—Angina pectoris—Doxorubicin—thyroid cancer	0.00207	0.00352	CcSEcCtD
Hydralazine—Pancytopenia—Doxorubicin—thyroid cancer	0.00202	0.00344	CcSEcCtD
Hydralazine—Neuropathy peripheral—Epirubicin—thyroid cancer	0.00201	0.00342	CcSEcCtD
Hydralazine—Jaundice—Epirubicin—thyroid cancer	0.002	0.0034	CcSEcCtD
Hydralazine—Conjunctivitis—Epirubicin—thyroid cancer	0.00199	0.00339	CcSEcCtD
Hydralazine—Neutropenia—Doxorubicin—thyroid cancer	0.00199	0.00338	CcSEcCtD
Hydralazine—Dysuria—Doxorubicin—thyroid cancer	0.00199	0.00338	CcSEcCtD
Hydralazine—Haematuria—Epirubicin—thyroid cancer	0.00196	0.00332	CcSEcCtD
Hydralazine—Weight decreased—Doxorubicin—thyroid cancer	0.00193	0.00327	CcSEcCtD
Hydralazine—Agranulocytosis—Epirubicin—thyroid cancer	0.00191	0.00325	CcSEcCtD
Hydralazine—RYR2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.0019	0.0166	CbGpPWpGaD
Hydralazine—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.00186	0.00316	CcSEcCtD
Hydralazine—Jaundice—Doxorubicin—thyroid cancer	0.00185	0.00314	CcSEcCtD
Hydralazine—Conjunctivitis—Doxorubicin—thyroid cancer	0.00185	0.00314	CcSEcCtD
Hydralazine—Hepatitis—Epirubicin—thyroid cancer	0.00184	0.00313	CcSEcCtD
Hydralazine—Hypoaesthesia—Epirubicin—thyroid cancer	0.00183	0.00311	CcSEcCtD
Hydralazine—Haematuria—Doxorubicin—thyroid cancer	0.00181	0.00308	CcSEcCtD
Hydralazine—Agranulocytosis—Doxorubicin—thyroid cancer	0.00177	0.00301	CcSEcCtD
Hydralazine—Flushing—Epirubicin—thyroid cancer	0.00171	0.0029	CcSEcCtD
Hydralazine—Hepatitis—Doxorubicin—thyroid cancer	0.0017	0.0029	CcSEcCtD
Hydralazine—Hypoaesthesia—Doxorubicin—thyroid cancer	0.0017	0.00288	CcSEcCtD
Hydralazine—Chills—Epirubicin—thyroid cancer	0.00165	0.00281	CcSEcCtD
Hydralazine—RYR2—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.0016	0.014	CbGpPWpGaD
Hydralazine—Flushing—Doxorubicin—thyroid cancer	0.00158	0.00269	CcSEcCtD
Hydralazine—Muscle spasms—Epirubicin—thyroid cancer	0.00154	0.00262	CcSEcCtD
Hydralazine—Chills—Doxorubicin—thyroid cancer	0.00153	0.0026	CcSEcCtD
Hydralazine—Ill-defined disorder—Epirubicin—thyroid cancer	0.00149	0.00253	CcSEcCtD
Hydralazine—Anaemia—Epirubicin—thyroid cancer	0.00148	0.00252	CcSEcCtD
Hydralazine—Agitation—Epirubicin—thyroid cancer	0.00147	0.0025	CcSEcCtD
Hydralazine—Malaise—Epirubicin—thyroid cancer	0.00145	0.00246	CcSEcCtD
Hydralazine—Leukopenia—Epirubicin—thyroid cancer	0.00144	0.00244	CcSEcCtD
Hydralazine—Muscle spasms—Doxorubicin—thyroid cancer	0.00143	0.00242	CcSEcCtD
Hydralazine—Palpitations—Epirubicin—thyroid cancer	0.00142	0.00241	CcSEcCtD
Hydralazine—Ill-defined disorder—Doxorubicin—thyroid cancer	0.00138	0.00234	CcSEcCtD
Hydralazine—Anaemia—Doxorubicin—thyroid cancer	0.00137	0.00233	CcSEcCtD
Hydralazine—Myalgia—Epirubicin—thyroid cancer	0.00136	0.00232	CcSEcCtD
Hydralazine—Arthralgia—Epirubicin—thyroid cancer	0.00136	0.00232	CcSEcCtD
Hydralazine—Agitation—Doxorubicin—thyroid cancer	0.00136	0.00232	CcSEcCtD
Hydralazine—Anxiety—Epirubicin—thyroid cancer	0.00136	0.00231	CcSEcCtD
Hydralazine—Discomfort—Epirubicin—thyroid cancer	0.00135	0.00229	CcSEcCtD
Hydralazine—Malaise—Doxorubicin—thyroid cancer	0.00134	0.00227	CcSEcCtD
Hydralazine—Leukopenia—Doxorubicin—thyroid cancer	0.00133	0.00226	CcSEcCtD
Hydralazine—Palpitations—Doxorubicin—thyroid cancer	0.00131	0.00223	CcSEcCtD
Hydralazine—Oedema—Epirubicin—thyroid cancer	0.00131	0.00222	CcSEcCtD
Hydralazine—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.0013	0.0114	CbGpPWpGaD
Hydralazine—Thrombocytopenia—Epirubicin—thyroid cancer	0.00128	0.00218	CcSEcCtD
Hydralazine—Tachycardia—Epirubicin—thyroid cancer	0.00128	0.00217	CcSEcCtD
Hydralazine—Myalgia—Doxorubicin—thyroid cancer	0.00126	0.00215	CcSEcCtD
Hydralazine—Arthralgia—Doxorubicin—thyroid cancer	0.00126	0.00215	CcSEcCtD
Hydralazine—Anxiety—Doxorubicin—thyroid cancer	0.00126	0.00214	CcSEcCtD
Hydralazine—Discomfort—Doxorubicin—thyroid cancer	0.00125	0.00212	CcSEcCtD
Hydralazine—Anorexia—Epirubicin—thyroid cancer	0.00125	0.00212	CcSEcCtD
Hydralazine—Hypotension—Epirubicin—thyroid cancer	0.00122	0.00208	CcSEcCtD
Hydralazine—Oedema—Doxorubicin—thyroid cancer	0.00121	0.00206	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00119	0.00203	CcSEcCtD
Hydralazine—Thrombocytopenia—Doxorubicin—thyroid cancer	0.00119	0.00201	CcSEcCtD
Hydralazine—Tachycardia—Doxorubicin—thyroid cancer	0.00118	0.00201	CcSEcCtD
Hydralazine—Paraesthesia—Epirubicin—thyroid cancer	0.00117	0.002	CcSEcCtD
Hydralazine—Dyspnoea—Epirubicin—thyroid cancer	0.00117	0.00198	CcSEcCtD
Hydralazine—Anorexia—Doxorubicin—thyroid cancer	0.00115	0.00196	CcSEcCtD
Hydralazine—Dyspepsia—Epirubicin—thyroid cancer	0.00115	0.00196	CcSEcCtD
Hydralazine—Decreased appetite—Epirubicin—thyroid cancer	0.00114	0.00193	CcSEcCtD
Hydralazine—Hypotension—Doxorubicin—thyroid cancer	0.00113	0.00192	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00113	0.00192	CcSEcCtD
Hydralazine—Constipation—Epirubicin—thyroid cancer	0.00112	0.0019	CcSEcCtD
Hydralazine—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.0011	0.00187	CcSEcCtD
Hydralazine—Paraesthesia—Doxorubicin—thyroid cancer	0.00109	0.00185	CcSEcCtD
Hydralazine—Dyspnoea—Doxorubicin—thyroid cancer	0.00108	0.00183	CcSEcCtD
Hydralazine—Feeling abnormal—Epirubicin—thyroid cancer	0.00108	0.00183	CcSEcCtD
Hydralazine—Dyspepsia—Doxorubicin—thyroid cancer	0.00107	0.00181	CcSEcCtD
Hydralazine—Decreased appetite—Doxorubicin—thyroid cancer	0.00105	0.00179	CcSEcCtD
Hydralazine—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00105	0.00178	CcSEcCtD
Hydralazine—Urticaria—Epirubicin—thyroid cancer	0.00104	0.00177	CcSEcCtD
Hydralazine—Constipation—Doxorubicin—thyroid cancer	0.00104	0.00176	CcSEcCtD
Hydralazine—Body temperature increased—Epirubicin—thyroid cancer	0.00103	0.00176	CcSEcCtD
Hydralazine—Feeling abnormal—Doxorubicin—thyroid cancer	0.000998	0.0017	CcSEcCtD
Hydralazine—Hypersensitivity—Epirubicin—thyroid cancer	0.000964	0.00164	CcSEcCtD
Hydralazine—Urticaria—Doxorubicin—thyroid cancer	0.000962	0.00163	CcSEcCtD
Hydralazine—Body temperature increased—Doxorubicin—thyroid cancer	0.000957	0.00163	CcSEcCtD
Hydralazine—Pruritus—Epirubicin—thyroid cancer	0.000926	0.00157	CcSEcCtD
Hydralazine—Diarrhoea—Epirubicin—thyroid cancer	0.000895	0.00152	CcSEcCtD
Hydralazine—Hypersensitivity—Doxorubicin—thyroid cancer	0.000892	0.00152	CcSEcCtD
Hydralazine—Dizziness—Epirubicin—thyroid cancer	0.000865	0.00147	CcSEcCtD
Hydralazine—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000858	0.0075	CbGpPWpGaD
Hydralazine—Pruritus—Doxorubicin—thyroid cancer	0.000857	0.00146	CcSEcCtD
Hydralazine—Vomiting—Epirubicin—thyroid cancer	0.000832	0.00141	CcSEcCtD
Hydralazine—Diarrhoea—Doxorubicin—thyroid cancer	0.000828	0.00141	CcSEcCtD
Hydralazine—Rash—Epirubicin—thyroid cancer	0.000825	0.0014	CcSEcCtD
Hydralazine—Dermatitis—Epirubicin—thyroid cancer	0.000824	0.0014	CcSEcCtD
Hydralazine—Headache—Epirubicin—thyroid cancer	0.00082	0.00139	CcSEcCtD
Hydralazine—Dizziness—Doxorubicin—thyroid cancer	0.000801	0.00136	CcSEcCtD
Hydralazine—Nausea—Epirubicin—thyroid cancer	0.000777	0.00132	CcSEcCtD
Hydralazine—Vomiting—Doxorubicin—thyroid cancer	0.00077	0.00131	CcSEcCtD
Hydralazine—Rash—Doxorubicin—thyroid cancer	0.000763	0.0013	CcSEcCtD
Hydralazine—Dermatitis—Doxorubicin—thyroid cancer	0.000763	0.0013	CcSEcCtD
Hydralazine—Headache—Doxorubicin—thyroid cancer	0.000758	0.00129	CcSEcCtD
Hydralazine—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000756	0.00661	CbGpPWpGaD
Hydralazine—Nausea—Doxorubicin—thyroid cancer	0.000719	0.00122	CcSEcCtD
Hydralazine—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000519	0.00453	CbGpPWpGaD
Hydralazine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000516	0.00451	CbGpPWpGaD
Hydralazine—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00042	0.00368	CbGpPWpGaD
Hydralazine—CYP3A4—Biological oxidations—RXRA—thyroid cancer	0.000223	0.00195	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—MINPP1—thyroid cancer	0.000164	0.00143	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—NDUFA13—thyroid cancer	0.00014	0.00122	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—CHST14—thyroid cancer	0.000131	0.00115	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—HPGD—thyroid cancer	0.000106	0.000924	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—TPR—thyroid cancer	6.07e-05	0.000531	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	5.97e-05	0.000522	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—SLC5A5—thyroid cancer	4.55e-05	0.000397	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—RXRA—thyroid cancer	3.82e-05	0.000334	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PPARG—thyroid cancer	2.41e-05	0.000211	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.9e-05	0.000166	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—PTEN—thyroid cancer	1.65e-05	0.000145	CbGpPWpGaD
Hydralazine—CYP3A4—Metabolism—AKT1—thyroid cancer	9.53e-06	8.34e-05	CbGpPWpGaD
